Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Sports Medicine
Erschienen in: Sports Medicine 7/2013

01.07.2013 | Review Article

Skin Conditions of Baseball, Cricket, and Softball Players

verfasst von: Joshua A. Farhadian, Brook E. Tlougan, Brian B. Adams, Jonathan S. Leventhal, Miguel R. Sanchez

Erschienen in: Sports Medicine | Ausgabe 7/2013

Einloggen, um Zugang zu erhalten

Abstract

Each year in the United States over 80 million people participate in bat-and-ball sports, for example baseball and softball. Cricket, the world’s second most popular sport, is enjoyed by hundreds of millions of participants in such countries as India, Pakistan, Australia, New Zealand, Bangladesh, South Africa, West Indies, Sri Lanka, United Kingdom, and Zimbabwe. Although any player can develop skin disease as a result of participation in these bat-and-ball sports, competitive team athletes are especially prone to skin problems related to infection, trauma, allergy, solar exposure, and other causes. These diseases can produce symptoms that hinder individual athletic performance and participation. In this review, we discuss the diagnosis and best-practice management of skin diseases that can develop as a result of participation in baseball, softball, and cricket.

Literatur
  1. Boden BP, Tacchetti R, Mueller FO. Catastrophic injuries in high school and college baseball players. Am J Sports Med. 2004;32(5):1189–96.PubMedView Article
  2. International Baseball Federation. IBAF number book. 2011 [cited 2012 October 1]. http://​www.​ibaf.​org/​en/​infopage-detail.​aspx?​id=​6ce46799-80df-41f5-848b-2f10a25479ee.
  3. Tator CH. Catastrophic injuries in sports and recreation: causes and prevention: a Canadian study. Canada: University of Toronto Press; 2008.
  4. Janda DH. The prevention of baseball and softball injuries. Clin Orthop. 2003;409(Journal Article):20.
  5. Association NSG. Report on Sports Participation. 2011.
  6. Walker HL, Carr DJ, Chalmers DJ, et al. Injury to recreational and professional cricket players: circumstances, type and potential for intervention. Accid Anal Prev. 2010;42(6):2094–8.PubMedView Article
  7. Cricket Australia. National Cricket Census 2011/12. Australia; 2012.
  8. England and Wales Cricket Board. Participation. 2012 [cited 2012 December 25]. http://​www.​ecb.​co.​uk/​development/​get-into-cricket/​participation/​.
  9. Rice SG, Congeni JA. Baseball and softball. Pediatrics. 2012;129(3):e842–56.PubMedView Article
  10. Padmanabhan RA, Fraser TG. The emergence of methicillin-resistant Staphylococcus aureus in the community. Cleve Clin J Med. 2005;72(3):235–41.PubMedView Article
  11. Cohen PR. Community-acquired methicillin-resistant Staphylococcus aureus skin infections: implications for patients and practitioners. Am J Clin Dermatol. 2007;8(5):259–70.PubMedView Article
  12. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41(10):1373–406.PubMedView Article
  13. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18.PubMedView Article
  14. Luelmo-Aguilar J, Santandreu MS. Folliculitis: recognition and management. Am J Clin Dermatol. 2004;5(5):301–10.PubMedView Article
  15. Adams BB. Skin infections in athletes. Dermatol Nurs. 2008;20(1):39.PubMed
  16. Kazakova SV, Hageman JC, Matava M, et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med. 2005;352(5):468–75.PubMedView Article
  17. Morgan M. Treatment of MRSA soft tissue infections: an overview. Injury. 2011;42(Journal Article):S11–S7.
  18. Chon SY, Doan HQ, Ma R, et al. Antibiotic overuse and resistance in dermatology. Dermatol Ther. 2012;25(1):55–69.PubMedView Article
  19. NiRiain U. Recommended management of common bacterial skin infections. Prescriber. 2011;22(15-16):14–24.View Article
  20. Oranje AP, Chosidow O, Sacchidanand S, et al. Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study. Dermatology. 2007;215(4):331–40.PubMedView Article
  21. Koning S, Verhagen AP, van Suijlekom-Smit LW, et al. Interventions for impetigo. Cochrane Database Syst Rev. 2003;2(Journal Article).
  22. Woodford N, Afzal-Shah M, Warner M, et al. In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin. J Antimicrob Chemother. 2008;62(4):766–8.PubMedView Article
  23. Frithsen IL, Salgado CD. Uncomplicated skin and soft tissue infections. Manag Antimicrob Infect Dis. 2010(Journal Article):301–12.
  24. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis. 2003;36(2):131.PubMedView Article
  25. Yang ES, Tan J, Eells S, et al. Body site colonization in patients with community associated methicillin-resistant Staphylococcus aureus and other types of S. aureus skin infections. Clin Microbiol. Infect. 2010;16(5):425–31.
  26. Klempner MS, Styrt B. Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy. JAMA. 1988;260(18):2682–5.PubMedView Article
  27. Falagas ME, Bliziotis IA, Fragoulis KN. Oral rifampin for eradication of Staphylococcus aureus carriage from healthy and sick populations: a systematic review of the evidence from comparative trials. Am J Infect Control. 2007;35(2):106–14.PubMedView Article
  28. Conklin RJ. Common cutaneous disorders in athletes. Sports Med. 1990;9(2):100–19.PubMedView Article
  29. McDaniel WE. Tinea versicolor. Arch Dermatol. 1977;113(4):519–20.PubMedView Article
  30. McKeag D. Basketball. Indianapolis: Blackwell Science; 2003.
  31. Pharis DB, Teller C, Wolf JE Jr. Cutaneous manifestations of sports participation. J Am Acad Dermatol. 1997;36(3):448–59.PubMedView Article
  32. Morishita N, Sei Y. Microreview of Pityriasis versicolor and Malassezia species. Mycopathologia. 2006;162(6):373–6.PubMedView Article
  33. Prohic A, Ozegovic L. Malassezia species isolated from lesional and non-lesional skin in patients with pityriasis versicolor. Mycoses. 2007;50(1):58–63.PubMedView Article
  34. Baron DA, Martin DM, Magd SA. Doping in sports and its spread to at-risk populations: an international review. World Psychiatry. 2007;6(2):118.PubMed
  35. Walker J, Adams B. Cutaneous manifestations of anabolic–androgenic steroid use in athletes. Int J Dermatol. 2009;48(10):1044–8.PubMedView Article
  36. Terney R, McLain LG. The use of anabolic steroids in high school students. Arch Pediatr Adolesc Med. 1990;144(1):99.View Article
  37. Lorang M, Callahan B, Cummins KM, et al. Anabolic androgenic steroid use in teens: prevalence, demographics, and perception of effects. J Child Adolesc Subst Abuse. 2011;20(4):358–69.View Article
  38. Scott MJ 3rd, Scott AM. Effects of anabolic-androgenic steroids on the pilosebaceous unit. Cutis. 1992;50(2):113–6.PubMed
  39. Gupta AK, Batra R, Bluhm R, et al. Pityriasis versicolor. Dermatol Clin. 2003;21(3):413–29, v–vi.
  40. Faergemann J, Fredriksson T. Tinea versicolor: some new aspects on etiology, pathogenesis, and treatment. Int J Dermatol. 1982;21(1):8–12.PubMedView Article
  41. Durdu M, Ilkit M. First step in the differential diagnosis of folliculitis: cytology. Crit Rev Microbiol. 2012;00:1–17.
  42. Schwartz RA. Superficial fungal infections. Lancet. 2004;364(9440):1173–82.PubMedView Article
  43. Hu SW, Bigby M. Pityriasis versicolor: a systematic review of interventions. Arch Dermatol. 2010;146(10):1132.PubMedView Article
  44. Sánchez JL, Torres VM. Double-blind efficacy study of selenium sulfide in tinea versicolor. J Am Acad Dermatol. 1984;11(2):235–8.PubMedView Article
  45. Savin RC, Horwitz SN. Double-blind comparison of 2% ketoconazole cream and placebo in the treatment of tinea versicolor. J Am Acad Dermatol. 1986;15(3):500–3.PubMedView Article
  46. Goodless DR, Ramos-Caro FA, Flowers FP. Ketoconazole in the treatment of pityriasis versicolor: international review of clinical trials. Ann Pharmacother. 1991;25(4):395–8.
  47. Köse O, Tastan HB, Gür AR, et al. Comparison of a single 400 mg dose versus a 7-day 200 mg daily dose of itraconazole in the treatment of tinea versicolor. J Dermatol Treat. 2002;13(2):77–9.View Article
  48. Amer MA. Fluconazole in the treatment of tinea versicolor. Int J Dermatol. 1997;36(12):940–2.PubMedView Article
  49. Difonzo EM. Italian multicentre study with oral itraconazole in recurrent pityriasis versicolor, preliminary report. J Eur Acad Dermatol Venereol. 1992;1(5):S19–20.View Article
  50. Watanabe S, Harada T, Hiruma M, et al. Epidemiological survey of foot diseases in Japan: results of 30,000 foot checks by dermatologists. J Dermatol. 2010;37(5):397–406.PubMedView Article
  51. Kemna ME, Elewski BE. A U.S. epidemiologic survey of superficial fungal diseases. J Am Acad Dermatol. 1996;35(4):539–42.PubMedView Article
  52. Foster KW, Ghannoum MA, Elewski BE. Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. J Am Acad Dermatol. 2004;50(5):748–52.PubMedView Article
  53. English MP, Gibson MD. Studies in the epidemiology of tinea pedis. Br Med J. 1959;1(5135):1442–6.PubMedView Article
  54. Attye A, Auger P, Joly J. Incidence of occult athlete’s foot in swimmers. Eur J Epidemiol. 1990;6(3):244–7.PubMedView Article
  55. Bolanos B. Dermatophyte feet infection among students enrolled in swimming courses at a university pool. Boletin de la Asociacion Medica de Puerto Rico. 1991;83(5):181–4.PubMed
  56. Gentles JC, Evans EGV, Jones GR. Control of tinea pedis in a swimming bath. Br Med J. 1974;2(5919):577–80.PubMedView Article
  57. Adams BB. Fungal skin infections. Sports Dermatology. New York: Springer; 2006. p. 203–80.
  58. Field LA, Adams BB. Tinea pedis in athletes. Int J Dermatol. 2008;47(5):485–92.PubMedView Article
  59. Weinstein A, Berman B. Topical treatment of common superficial tinea infections. Am Fam Phys. 2002;65(10):2095–102.
  60. Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev. 2007;3:CD001434. doi:10.​1002/​14651858.​CD001434.​pub2.
  61. Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia. 2008;166(5):353–67.PubMedView Article
  62. De Keyser P, De Backer M, Massart DL, et al. Two-week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): a double-blind, multicentre study. Br J Dermatol. 1994;130 Suppl 43(Journal Article):22–5.
  63. Gupta AK, Doncker PD, Heremans A, et al. Itraconazole for the treatment of tinea pedis: a dosage of 400 mg/day given for 1 week is similar in efficacy to 100 or 200 mg/day given for 2 to 4 weeks. J Am Acad Dermatol. 1997;36(5 Pt 1):789–92.PubMedView Article
  64. Aguila R, Montero Gei F, Robles M, et al. Once-weekly oral doses of fluconazole 150 mg in the treatment of tinea pedis. Clin Exp Dermatol. 1992;17(6):402–6.
  65. Odom R. Pathophysiology of dermatophyte infections. J Am Acad Dermatol. 1993;28(5 Pt 1):S2–7.PubMedView Article
  66. Levine N. Dermatologic aspects of sports medicine. J Am Acad Dermatol. 1980;3(4):415–24.PubMedView Article
  67. Beck CK. Infectious diseases in sports. Med Sci Sports Exerc. 2000;32(7):S431.PubMed
  68. Thomas J, Jacobson GA, Narkowicz CK, et al. Toenail onychomycosis: an important global disease burden. J Clin Pharm Ther. 2010;35(5):497–519.PubMedView Article
  69. Rodríguez-Pazos L, Pereiro-Ferreirós MM, Pereiro M, et al. Onychomycosis observed in children over a 20-year period. Mycoses. 2011;54(5):450–3.PubMedView Article
  70. Purim KS, Bordignon GP, Queiroz-Telles F. Fungal infection of the feet in soccer players and non-athlete individuals. Rev Iberoam Micol. 2005;22(Journal Article):34–8.
  71. Caputo R, De Boulle K, Del Rosso J, et al. Prevalence of superficial fungal infections among sports-active individuals: results from the Achilles survey, a review of the literature. J Eur Acad Dermatol Venereol. 2001;15(4):312–6.PubMed
  72. Zaias N. Clinical manifestations of onychomycosis. Clin Exp Dermatol. 1992;17(Journal Article):6–7.
  73. Weinberg JM, Koestenblatt EK, Tutrone WD, et al. Comparison of diagnostic methods in the evaluation of onychomycosis. J Am Acad Dermatol. 2003;49(2):193–7.PubMedView Article
  74. Szepietowski JC, Reich A, Garlowska E, et al. Factors influencing coexistence of toenail onychomycosis with tinea pedis and other dermatomycoses: a survey of 2761 patients. Arch Dermatol. 2006;142(10):1279.PubMedView Article
  75. Lauharanta J. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol. 1992;17(Suppl 1):41–3.PubMedView Article
  76. Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol. 2004;150(3):537–44.PubMedView Article
  77. Elewski B, Pollak R, Ashton S, et al. A randomized, placebo-and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br J Dermatol. 2012;166(2):389–98.PubMedView Article
  78. Esterowitz D, Greer KE, Cooper PH, et al. Plantar warts in the athlete. Am J Emerg Med. 1995;13(4):441–3.PubMedView Article
  79. Squires S. Orioles pitcher among wart casualties. Washington Post. 1998; Sect. Z09.
  80. Roach MC, Chretien JH. Common hand warts in athletes: association with trauma to the hand. J Am Coll Health. 1995;44(3):125–6.PubMedView Article
  81. Sterling JC, Handfield-Jones S, Hudson PM. Guidelines for the management of cutaneous warts. Br J Dermatol. 2001;144(1):4–11.PubMedView Article
  82. Bunney MH, Nolan MW, Williams DA. An assessment of methods of treating viral warts by comparative treatment trials based on a standard design. Br J Dermatol. 1976;94(6):667–79.PubMedView Article
  83. Parish LC, Monroe E, Rex IH Jr. Treatment of common warts with high-potency (26%) salicylic acid. Clin Ther. 1988;10(4):462–6.PubMed
  84. Coskey RJ. Treatment of plantar warts in children with a salicylic acid-podophyllin-cantharidin product. Pediatr Dermatol. 1984;2(1):71–3.PubMedView Article
  85. Phelps WC, Alexander KA. Antiviral therapy for human papillomaviruses: rationale and prospects. Ann Intern Med. 1995;123(5):368.PubMedView Article
  86. Muzio G, Massone C, Rebora A. Treatment of non-genital warts with topical imiquimod 5% cream. Eur J Dermatol. 2002;12(4):347–9.PubMed
  87. Johnson SM, Roberson PK, Horn TD. Intralesional injection of mumps or Candida skin test antigens: a novel immunotherapy for warts. Arch Dermatol. 2001;137(4):451.PubMed
  88. Tlougan BE, Mancini AJ, Mandell JA, et al. Skin conditions in figure skaters, ice-hockey players and speed skaters: part II—cold-induced, infectious and inflammatory dermatoses. Sports Med. 2011;41(11):967–84.PubMedView Article
  89. Kwok CS, Holland R, Gibbs S. Efficacy of topical treatments for cutaneous warts: a meta analysis and pooled analysis of randomized controlled trials. Br J Dermatol. 2011;165(2):233–46.
  90. Dreazen JR, Mulhem E. Electrodesiccation and curettage for removal of nongenital warts. Am Fam Phys. 2012;85(8):e2.
  91. Clifton MM, Johnson SM, Roberson PK, et al. Immunotherapy for recalcitrant warts in children using intralesional mumps or Candida antigens. Pediatr Dermatol. 2003;20(3):268–71.PubMedView Article
  92. Horn TD, Johnson SM, Helm RM, et al. Intralesional immunotherapy of warts with mumps, Candida, and Trichophyton skin test antigens: a single-blinded, randomized, and controlled trial. Arch Dermatol. 2005;141(5):589.PubMedView Article
  93. Rutala W, Weber DJ. Guidelines for disinfection and sterilization in healthcare facilities. Atlanta: Center for Disease Control; 2008.
  94. Knapik JJ, Reynolds KL, Duplantis KL, et al. Friction blisters. Pathophysiology, prevention and treatment. Sports Med. 1995;20(3):136–47.PubMedView Article
  95. Akers WA, Sulzberger MB. The friction blister. Plast Reconstr Surg. 1972;50(1):98.
  96. Brennan FH Jr. Managing blisters in competitive athletes. Curr Sports Med Rep. 2002;1(6):319–22.PubMed
  97. Pecci M, Comeau D, Chawla V. Skin conditions in the athlete. Am J Sports Med. 2009;37(2):406–18.PubMedView Article
  98. Fine JD, Eady RA, Bauer EA, et al. Revised classification system for inherited epidermolysis bullosa: Report of the Second International Consensus Meeting on diagnosis and classification of epidermolysis bullosa. J Am Acad Dermatol. 2000;42(6):1051–66.PubMedView Article
  99. Chun YI, Jang IS, Park SS, et al. A case of epidermolysis bullosa (Weber-Cockayne Type). Korean J Dermatol. 1985;23(4):503–6.
  100. Cortese TA Jr, Fukuyama K, Epstein W, et al. Treatment of friction blisters: an experimental study. Arch Dermatol. 1968;97(6):717.PubMedView Article
  101. Hoeffler DF. Friction blisters and cellulitis in a navy recruit population. Mil Med. 1975;140(5):333–7.PubMed
  102. Adams BB. Friction injuries to the skin. Sports Dermatology. New York: Springer; 2006. p. 203–40.
  103. Mailler EA, Adams BB. The wear and tear of 26.2: dermatological injuries reported on marathon day. Br J Sports Med. 2004;38(4):498–501.PubMedView Article
  104. Inui S, Yamamoto S, Ikegami R, et al. Baseball pitcher’s friction dermatitis. Contact Dermat. 2002;47(3):176–7.View Article
  105. Uchiyama M, Tsuboi R, Mitsuhashi Y. Athlete’s nodule. J Dermatol. 2009;36(11):608–11.PubMedView Article
  106. Cohen PR, Eliezri YD, Silvers DN. Athlete’s nodules: sports-related connective tissue nevi of the collagen type (collagenomas). Cutis. 1992;50(2):131–5.PubMed
  107. Erickson JG, von Gemmingen GR. Surfer’s nodules and other complications of surfboarding. JAMA. 1967;201(2):134–6.PubMedView Article
  108. Paller AS, Hebert AA. Knuckle pads in children. Arch Pediatr Adolesc Med. 1986;140(9):915.View Article
  109. Adams BB. Sports dermatology: prevention. In: Norman R, editor. Preventive dermatology. London: Springer; 2010. p. 161–71.
  110. Borelli C, Bielfeldt S, Borelli S, et al. Cream or foam in pedal skin care: towards the ideal vehicle for urea used against dry skin. Int J Cosmet Sci. 2011;33(1):37–43.PubMedView Article
  111. Ademola J. Clinical evaluation of 40% urea and 12% ammonium lactate in the treatment of xerosis. Am J Clin Dermatol. 2002;3(Journal Article):217–22.
  112. Akdemir O, Bilkay U, Tiftikcioglu YO, et al. New alternative in treatment of callus. J Dermatol. 2011;38(2):146–50.PubMedView Article
  113. Singh D, Bentley G, Trevino SG. Callosities, corns, and calluses. Br Med J. 1996;312(7043):1403.
  114. Bae JM, Kang H, Kim HO, et al. Differential diagnosis of plantar wart from corn, callus and healed wart with the aid of dermoscopy. Br J Dermatol. 2009;160(1):220–2.PubMedView Article
  115. Basler RS. Acne mechanica in athletes. Cutis. 1992;50(2):125–8.PubMed
  116. Cordoro K, Ganz J. Training room management of medical conditions: sports dermatology. Clin Sports Med. 2005;24(3):565–98. (viii).PubMedView Article
  117. Fitzpatrick TB, Wolff K. Fitzpatrick’s dermatology in general medicine. New York: McGraw–Hill Medical; 2008.
  118. Basler RSW. Skin injuries in sports medicine. J Am Acad Dermatol. 1989;21(6):1257–62.PubMedView Article
  119. Birrer RB, Griesemer B, Cataletto MB. Pediatric sports medicine for primary care. Philadelphia: Lippincott Williams & Wilkins; 2002.
  120. Tlougan BE, Mancini AJ, Mandell JA, et al. Skin conditions in figure skaters, ice-hockey players and speed skaters: part I—mechanical dermatoses. Sports Med. 2011;41(9):709–19.PubMedView Article
  121. Urbina F, Leon L, Sudy E. Black heel, talon noir or calcaneal petechiae? Australas J Dermatol. 2008;49(3):148–51.PubMedView Article
  122. Zalaudek I, Argenziano G, Soyer HP, et al. Dermoscopy of subcorneal hematoma. Dermatol Surg. 2004;30(9):1229–32.PubMedView Article
  123. Mailler-Savage EA, Adams BB. Skin manifestations of running. J Am Acad Dermatol. 2006;55(2):290–301.PubMedView Article
  124. Adams BB. Jogger’s toenail. J Am Acad Dermatol. 2003;48(5):S58–9.PubMedView Article
  125. Colver GB, Ryan TJ. Acquired port-wine stain. Arch Dermatol. 1986;122(12):1415–6.PubMedView Article
  126. Adams BB, Lucky AW. Acquired port-wine stains and antecedent trauma: case report and review of the literature. Arch Dermatol. 2000;136(7):897–9.PubMedView Article
  127. Rosen S, Smoller BR. Port-wine stains: a new hypothesis. J Am Acad Dermatol. 1987;17(1):164–6.PubMedView Article
  128. Lanigan S. Acquired port wine stains: clinical and psychological assessment and response to pulsed dye laser therapy. Br J Dermatol. 1997;137(1):86–90.PubMedView Article
  129. Aalto-Korte K, Välimaa J, Henriks-Eckerman ML, et al. Allergic contact dermatitis from salicyl alcohol and salicylaldehyde in aspen bark (Populus tremula). Contact Dermat. 2005;52(2):93–5.View Article
  130. Acebo E, Ratón JA, Sautúa S, et al. Allergic contact dermatitis from Boswellia serrata extract in a naturopathic cream. Contact Dermat. 2004;51(2):91–2.View Article
  131. Akyol A, Boyvat A, Kundakci N. Contact sensitivity to aluminum. Int J Dermatol. 2004;43(12):942–3.PubMedView Article
  132. Corazza M, Zauli S, Pagnoni A, et al. Allergic contact dermatitis caused by metals in blackboard chalk: a case report. Acta Derm Venereol. 2012;92(4):436–7.PubMedView Article
  133. Curley RK, Macfarlane AW, King CM. Contact sensitivity to the amide anesthetics lidocaine, prilocaine, and mepivacaine: case report and review of the literature. Arch Dermatol. 1986;122(8):924.PubMedView Article
  134. Downs AMR, Sansom JE. Colophony allergy: a review. Contact Dermat. 1999;41(6):305–10.View Article
  135. Frangella C, Chiaradia G, Rizzi A, et al. Allergic risk in sport: public health issues. Sport Sci Health. 2011;6(2):77–84.View Article
  136. Gan SL, Goh CL, Lee CS, et al. Occupational dermatosis among sanders in the furniture industry. Contact Dermat. 1987;17(4):237–40.View Article
  137. Kockentiet B, Adams BB. Contact dermatitis in athletes. J Am Acad Dermatol. 2007;56(6):1048–55.PubMedView Article
  138. Park HJ, Kang HA, Lee JY, et al. Allergic contact dermatitis from benzalkonium chloride in an antifungal solution. Contact Dermat. 2000;42(5):306–7.
  139. Smith RG. Shoe dermatitis: a review of current concepts. Foot. 2008;18(1):40–7.View Article
  140. Steinkjer B, Braathen LR. Contact dermatitis from triclosan (Irgasan DP 300). Contact Dermat. 1988;18(4):243–4.View Article
  141. Tan KS, Mitchell JC. Patch and photopatch tests in contact dermatitis and photodermatitis: a preliminary report of investigation of 150 patients, with special reference to “cedar-poisoning”. Can Med Assoc J. 1968;98(5):252.PubMed
  142. Vokoun FJ. Linseed oil dermatitis. JAMA. 1927;89(1):20.View Article
  143. Zug KA, Warshaw EM, Fowler JF Jr, et al. Patch-test results of the North American contact dermatitis group 2005–2006. Dermatitis. 2009;20(3):149.PubMed
  144. Beltrani VS. The clinical spectrum of atopic dermatitis. J Allergy Clin Immunol. 1999;104(3, supplement):S87–98.PubMedView Article
  145. Weston WL, Bruckner A. Allergic contact dermatitis. Pediatr Clin N Am. 2000;47(4):897–907.View Article
  146. Emmett EA, Risby TH, Taylor J, et al. Skin elicitation threshold of ethylbutyl thiourea and mercaptobenzothiazole with relative leaching from sensitizing products. Contact Dermat. 1994;30(2):85–90.View Article
  147. Shackelford KE, Belsito DV. The etiology of allergic-appearing foot dermatitis: A 5-year retrospective study. J Am Acad Dermatol. 2002;47(5):715–21.PubMedView Article
  148. Lubach D, Bensmann A, Bornemann U. Steroid-induced dermal atrophy. Dermatology. 1989;179(2):67–72.View Article
  149. Commens C, McGeogh A, Bartlett B, et al. Bindii (Jo Jo) dermatitis (Soliva pterosperma [Compositae]). J Am Acad Dermatol. 1984;10(5 Pt 1):768–73.PubMedView Article
  150. Commens CA, Bartlett BH, McGeoch AH, et al. Bindii (jo-jo) dermatitis the clinical and histopathological spectrum. Australas J Dermatol. 1982;23(3):110–5.PubMedView Article
  151. Hogan PA. Bindii dermatitis. Australas J Dermatol. 1997;38(4):224–5.PubMedView Article
  152. Mitchell GJ. Report to the commissioner of baseball of an independent investigation into the illegal use of steroids and other performance enhancing substances by players in major league baseball: Office of the Commissioner of Baseball New York; 2007.
  153. O’Sullivan AJ, Kennedy MC, Casey JH, et al. Anabolic-androgenic steroids: medical assessment of present, past and potential users. Med J Aust. 2000;173(6):323–7.PubMed
  154. Scott MJ Jr, Scott MJ 3rd. Dermatologists and anabolic-androgenic drug abuse. Cutis. 1989;44(1):30.PubMed
  155. Maravelias C, Dona A, Stefanidou M, et al. Adverse effects of anabolic steroids in athletes: a constant threat. Toxicol Lett. 2005;158(3):167–75.PubMedView Article
  156. Kuhn CM. Anabolic steroids. Recent Prog Horm Res. 2002;57(1):411–34.PubMedView Article
  157. Green GA. Doping control for the team physician. Am J Sports Med. 2006;34(10):1690–8.PubMedView Article
  158. Evans NA. Current concepts in anabolic-androgenic steroids. Am J Sports Med. 2004;32(2):534–42.PubMedView Article
  159. British Medical Journal. Best practice guidelines: anabolic steroid abuse. 2012 [cited 2012 Web Page]. http://​bestpractice.​bmj.​com/​best-practice/​monograph/​987/​basics.​html.
  160. Kang S. Topical tretinoin therapy for management of early striae. J Am Acad Dermatol. 1998;39(2):S90–2.PubMedView Article
  161. Fox JL. Pulse dye laser eliminates stretch marks. Cosmet Derm. 1997;10(Journal Article):51–2.
  162. Goldman A, Rossato FAV, Prati C. Stretch marks: treatment using the 1,064-nm Nd: YAG laser. Dermatol Surg. 2008;34(5):686–92.PubMedView Article
  163. Hernández-Pérez E, Colombo-Charrier E, Valencia-Ibiett E. Intense pulsed light in the treatment of striae distensae. Dermatol Surg. 2002;28(12):1124–30.PubMedView Article
  164. Hunter MH, Carek PJ. Evaluation and treatment of women with hirsutism. Am Fam Phys. 2003;67(12):2565–72.
  165. Melville SK, Rosenthal FS, Luckmann R, et al. Quantitative ultraviolet skin exposure in children during selected outdoor activities. Photodermatol Photoimmunol Photomed. 1991;8(3):99–104.PubMed
  166. Han A, Maibach HI. Management of acute sunburn. Am J Clin Dermatol. 2004;5(1):39–47.PubMedView Article
  167. American Academy of Dermatology. Sunscreens. 2012 [cited 2012 Web Page]. http://​www.​aad.​org/​media-resources/​stats-and-facts/​prevention-and-care/​sunscreens.
Metadaten
Titel
Skin Conditions of Baseball, Cricket, and Softball Players
verfasst von
Joshua A. Farhadian
Brook E. Tlougan
Brian B. Adams
Jonathan S. Leventhal
Miguel R. Sanchez
Publikationsdatum
01.07.2013
Verlag
Springer International Publishing AG
Erschienen in
Sports Medicine / Ausgabe 7/2013
Print ISSN: 0112-1642
Elektronische ISSN: 1179-2035
DOI
https://doi.org/10.1007/s40279-013-0022-4

Weitere Artikel der Ausgabe 7/2013

Sports Medicine 7/2013 Zur Ausgabe

Review Article

Catecholamines and Obesity: Effects of Exercise and Training

Correspondence

Authors’ Reply to Périard: “Cardiovascular Determinants Involved in Pacing Under Heat Stress”

Review Article

The Case for Driver Science in Motorsport: A Review and Recommendations

Systematic Review

The Importance of Trunk Muscle Strength for Balance, Functional Performance, and Fall Prevention in Seniors: A Systematic Review

Review Article

Methods of Prescribing Relative Exercise Intensity: Physiological and Practical Considerations

Review Article

What Do Athletes Drink During Competitive Sporting Activities?

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise